STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years

We aimed to determine the clinical characteristics and prognosis factors of young patients with gastric cancer (GC). A total of 101 young patients with GC referred to Zhengzhou University People's Hospital, Henan province, China between January 1st, 2003 and June 1st, 2015 were retrospectively reviewed. The medical records included ages, genders, marital status, family history of tumors, comorbidity, Helicobacter pylori (H.pylori) infection, fibrinogen, prealbumin, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), tumor location, tumor size, TNM stage, differentiation of the tumor, WHO type, treatment method and prognostic factors effect were further assessed. The mean age of GC patients in our group was 26.0 years. The incidence was slightly higher in females (female: male = 1.1:1). Some patients had the family history of tumor and H.pylori infection (2.0%, 6.9%). The tumor sizes were mainly under 5 cm (52.4%) and the most locations were in the antrum (43.5%) and body (42.5%). A large number of patients were diagnosed as adenocarcinomas (66.3%) and the main histological of GC was poor differentiated (72.3%). Moreover, a high proportion of patients were diagnosed at the stages III-IV (61.4%), and most patients received surgery combined chemotherapy (63.4%), however, the survival outcome was poor. In univariate Cox analysis, tumor sizes, TNM stage were significantly associated with overall survival (OS) and the multivariate Cox analysis demonstrated that TNM s...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Related Links:

In conclusion, in the dramatic rise of the esophageal adenocarcinoma incidence, obesity accompanied by reflux disease and the decreased incidence of H. pylori infection certainly play important roles. The introduction of modern antisecretory drugs in the treatment of acid-related diseases promoting carcinogenesis, arises as a new consideration. Orv Hetil. 2021; 162(51): 2040-2046.PMID:34898468 | DOI:10.1556/650.2021.32354
Source: Orvosi Hetilap - Category: General Medicine Authors: Source Type: research
In conclusion, in the dramatic rise of the esophageal adenocarcinoma incidence, obesity accompanied by reflux disease and the decreased incidence of H. pylori infection certainly play important roles. The introduction of modern antisecretory drugs in the treatment of acid-related diseases promoting carcinogenesis, arises as a new consideration. Orv Hetil. 2021; 162(51): 2040-2046.PMID:34898468 | DOI:10.1556/650.2021.32354
Source: Orvosi Hetilap - Category: General Medicine Authors: Source Type: research
In conclusion, in the dramatic rise of the esophageal adenocarcinoma incidence, obesity accompanied by reflux disease and the decreased incidence of H. pylori infection certainly play important roles. The introduction of modern antisecretory drugs in the treatment of acid-related diseases promoting carcinogenesis, arises as a new consideration. Orv Hetil. 2021; 162(51): 2040-2046.PMID:34898468 | DOI:10.1556/650.2021.32354
Source: Orvosi Hetilap - Category: General Medicine Authors: Source Type: research
Although environmental factors such as Helicobacter pylori, tobacco, and diet are major contributors to the development of gastric cancer (GC) worldwide, it is estimated that up to 5% to 10% of GC cases are due to an underlying hereditary susceptibility caused by germline pathogenic variants. Hereditary diffuse gastric cancer (HDGC) caused by germline pathogenic variants in the CDH1 gene is the principal familial GC syndrome. However, other well-established hereditary gastrointestinal syndromes have been associated with an increased risk of GC. In this review, we will discuss the latest insights and advances in our underst...
Source: Gastrointestinal Endoscopy Clinics of North America - Category: Gastroenterology Authors: Source Type: research
Purpose of review Gastric intestinal metaplasia (GIM) is an attractive target for surveillance and treatment as it can progress to gastric adenocarcinoma (GAC). Yet, GIM remains a challenging area for clinicians as most patients do not progress to cancer, and there are conflicting data regarding the benefits of surveillance and therapy. This review aims to summarize recently published GIM surveillance guidelines, to discuss, which patients with GIM may benefit from treatment, and to review pivotal and recent literature on GIM therapy. Recent findings Guidelines published by American, British, and European gastro...
Source: Current Opinion in Gastroenterology - Category: Gastroenterology Tags: STOMACH AND DUODENUM: Edited by Tilak U. Shah Source Type: research
Gastric cancer (GC) remains one of the most common and deadly cancers worldwide, even if its incidence has decreased over time, mainly because of prevention and treatment of Helicobacter pylori infection[1]. Contrarily, the incidence of gastro-esophageal junction (GEJ) adenocarcinomas has increased, attributable to smoking and elevated body mass index (BMI) [2]. Much progress has been made in the management of advanced G/GEJ adenocarcinomas: the identification of molecular sub-groups benefiting from specific therapies (HER2 positive tumors, MSI/dMMR and EBV positive tumors, FGFR amplified tumors, etc)[3 –6], the intr...
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research
Backert The pathogen Helicobacter pylori is the first reported bacterial type-1 carcinogen playing a role in the development of human malignancies, including gastric adenocarcinoma. Cancer cell motility is an important process in this scenario, however, the molecular mechanisms are still not fully understood. Here, we demonstrate that H. pylori subverts the actin-binding protein cortactin through its type-IV secretion system and injected oncoprotein CagA, e.g., by inducing tyrosine phosphorylation of cortactin at Y-470, which triggers gastric epithelial cell scattering and motility. During infection of AGS cells, corta...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
In this study, 100 gastric tissue samples from patients with gastric cancer were examined for detection of H. pylori and EBV in tumor tissue using PCR techniques, and the clinical relevance was statistically analyzed.RESULTS: Results revealed an individual Epstein-Barr virus (EBV) infection observed in (40 %) of gastric carcinoma cases. Furthermore, the frequency of EBV infection was significantly different with intestinal and diffuse gastric cancer types [15 % vs. 85 %;
Source: Annals of Medicine - Category: Internal Medicine Authors: Source Type: research
In this study, the lung adenocarcinoma patients and granuloma patients were treated as positive samples and negative samples, respectively. We used weighted accuracy to evaluate the RIPPER prediction performance, i.e., the average of the accuracies of positive samples and negative samples. Results The Discriminative MicroRNAs Between Lung Adenocarcinoma and Granuloma Patients in Whole Plasma, EV, and EV-Free Plasma The miRNA expression profiles of lung adenocarcinoma and granuloma patients in whole plasma, EV and EV-free plasma were analyzed separately. In whole plasma, the top 10 discriminative miRNAs were hsa-miR-223-...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.6 per 100,000 people and causing>3000 deaths/y. Clinical outcomes and response to “one size fits all” therapies are highly heterogeneous and thus a better stratification of patients may aid cancer treatment and response. The Gastric Cancer Task Force is a Chilean collaborative, noninterventional study that seeks to stratify gast...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | China Health | Gastric (Stomach) Cancer | Gastroenterology | Helicobacter Pylori | Hospitals | Internal Medicine | Study